Jardiance vs Lantus in Special Populations: A Head-to-Head Clinical Comparison

What Are Jardiance and Lantus, and How Do They Work?

Jardiance (empagliflozin) blocks the SGLT2 transporter in the proximal tubule, forcing ~70 grams of glucose per day into the urine and producing a mild osmotic diuresis. Lantus (insulin glargine U-100) is a recombinant, long-acting basal insulin that suppresses hepatic glucose output and stimulates peripheral glucose uptake over a 24-hour profile. The two drugs reach the same glycemic endpoint through entirely different biology.

Empagliflozin's Mechanism and Off-Target Benefits

The osmotic and natriuretic effects of SGLT2 inhibition reduce plasma volume by roughly 300 to 400 mL, lower systolic blood pressure by 3 to 5 mmHg, and cut uric acid levels. These hemodynamic changes likely explain part of the cardiovascular and renal benefit observed in outcome trials. The FDA approved empagliflozin in April 2014 for glycemic control, and later expanded labeling to include a cardiovascular mortality reduction indication and, in 2023, a heart failure with reduced ejection fraction (HFrEF) indication regardless of diabetes status. The full FDA prescribing information is available at accessdata.fda.gov.

Insulin Glargine's Mechanism and Duration Profile

Insulin glargine forms microprecipitates at the subcutaneous injection site, releasing insulin slowly over approximately 24 hours with no pronounced peak. The ORIGIN trial (N=12,537) demonstrated that glargine targeting fasting glucose <95 mg/dL did not increase cardiovascular events compared with standard care over 6.2 years 1. That neutrality on cardiovascular outcomes is clinically meaningful: it established the safety floor for long-term basal insulin use in patients with dysglycemia or early type 2 diabetes.

Head-to-Head Glycemic Efficacy

Neither drug is universally superior for HbA1c reduction. The choice depends on baseline glycemia, insulin secretory capacity, and patient preference.

HbA1c Outcomes in Large Trials

EMPA-REG OUTCOME enrolled 7,020 adults with type 2 diabetes and established cardiovascular disease. Patients on empagliflozin 10 mg or 25 mg achieved an adjusted mean HbA1c reduction of approximately 0.54% versus placebo at 206 weeks, on a background of standard-of-care antidiabetics that often included insulin 2. In ORIGIN, insulin glargine reduced HbA1c from 6.4% at baseline to 5.9% at 3 months and held it there for 6.2 years, confirming durable glycemic control across a long follow-up window 1.

Direct head-to-head RCT data comparing the two agents as monotherapy in matched populations are limited. A 2021 network meta-analysis in Diabetes Care pooled 453 trials and estimated that basal insulin produces roughly 1.0 to 1.5% greater HbA1c reduction than SGLT2 inhibitors in patients with baseline HbA1c above 9% 3. At baseline HbA1c below 8%, the gap narrows substantially.

Fasting Glucose vs. Postprandial Glucose

Lantus targets fasting plasma glucose directly by providing overnight hepatic glucose suppression. Empagliflozin lowers both fasting and postprandial glucose through glycosuria, though its absolute contribution to postprandial excursions is modest compared with short-acting agents. For patients whose HbA1c is driven predominantly by fasting hyperglycemia, glargine may be the more precise tool.

Cardiovascular Disease: The Population Where Empagliflozin Leads

Established or high-risk cardiovascular disease is the single population where empagliflozin has the strongest evidence advantage over basal insulin.

EMPA-REG OUTCOME Data

In EMPA-REG OUTCOME, empagliflozin reduced the primary MACE endpoint (cardiovascular death, nonfatal MI, nonfatal stroke) by 14% versus placebo (HR 0.86, 95% CI 0.74 to 0.99, P<0.001 for noninferiority; P=0.04 for superiority) 2. Cardiovascular death alone fell by 38% (HR 0.62, 95% CI 0.49 to 0.77). These benefits appeared within 3 months, well before meaningful HbA1c separation, suggesting the mechanism is largely hemodynamic rather than glycemic.

Insulin Glargine in Cardiovascular Patients

ORIGIN showed insulin glargine was cardiovascularly neutral (HR 1.02, 95% CI 0.94 to 1.11 for MACE) over 6.2 years 1. Neutral is not harmful. For a patient with established cardiovascular disease who also needs significant HbA1c reduction and is not tolerating SGLT2 inhibitors, glargine remains a reasonable option. The American Diabetes Association's 2024 Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, a GLP-1 receptor agonist or SGLT2 inhibitor with proven cardiovascular benefit is recommended." 4

Chronic Kidney Disease: Dosing Thresholds and Renoprotection

Empagliflozin in CKD

The EMPA-KIDNEY trial (N=6,609) tested empagliflozin 10 mg in patients with CKD (eGFR 20 to 44 or eGFR 45 to 90 with albuminuria). The drug reduced the composite of kidney disease progression or cardiovascular death by 28% (HR 0.72, 95% CI 0.64 to 0.82, P<0.001) 5. The FDA now permits empagliflozin use down to eGFR 20 mL/min/1.73m² based on this trial. Glycemic efficacy declines as eGFR falls below 45 because less glucose reaches the tubule, but renal and cardiovascular benefits persist.

Insulin Glargine in CKD

Insulin clearance drops by 25 to 50% as eGFR falls below 30 mL/min/1.73m², increasing hypoglycemia risk 6. Dose reductions of 25 to 50% are typically required in moderate-to-severe CKD. Patients on dialysis may need further empirical adjustments. Continuous glucose monitoring is advisable when titrating glargine below eGFR 30. The National Kidney Foundation's KDIGO 2022 Diabetes guidelines recommend SGLT2 inhibitors as first-line add-on therapy in patients with type 2 diabetes and CKD when eGFR permits, before considering intensification with insulin 7.

Heart Failure: A Class-Specific Advantage for Empagliflozin

HFrEF and HFpEF Evidence

EMPEROR-Reduced (N=3,730) showed empagliflozin 10 mg reduced the composite of cardiovascular death or hospitalization for heart failure by 25% (HR 0.75, 95% CI 0.65 to 0.86) in HFrEF patients, including those without diabetes 8. EMPEROR-Preserved (N=5,988) replicated this benefit in HFpEF, with a 21% relative risk reduction 9. These two trials led the FDA to approve empagliflozin for heart failure independent of glycemic status.

Why Insulin Glargine Is Used Cautiously in Heart Failure

Insulin promotes sodium and water retention through renal tubular mechanisms, which may worsen fluid overload in decompensated heart failure 10. This does not mean glargine is contraindicated, but patients with NYHA class III or IV heart failure need close volume monitoring during initiation or dose escalation. For the patient with type 2 diabetes plus heart failure, empagliflozin is the agent most guidelines now list first.

Elderly Patients (Age 65 and Older)

Older adults present competing risks: higher baseline cardiovascular disease favors empagliflozin, but reduced kidney function, polypharmacy, and fall risk from hypoglycemia or volume depletion complicate both choices.

Hypoglycemia Risk Comparison

Empagliflozin monotherapy causes hypoglycemia in roughly 0.4% of patients because it does not stimulate insulin secretion 2. Insulin glargine, by contrast, produced severe hypoglycemia in 1.0 events per 100 patient-years in ORIGIN and 0.31 events per 100 patient-years in lower-risk patients in the A1C-Derived Average Glucose (ADAG) sub-study 1. In elderly patients with cognitive impairment or irregular eating, hypoglycemia-driven falls can be catastrophic. The American Geriatrics Society 2023 Beers Criteria flag sulfonylureas and sliding-scale insulin as high-risk in older adults, and note that basal insulin titration requires extra caution 11.

Volume Depletion and UTI Risk in Older Adults

Empagliflozin's diuretic effect can precipitate orthostatic hypotension in elderly patients already on loop diuretics or ACE inhibitors. Genital mycotic infections occur in roughly 6 to 10% of women and 3 to 5% of men on SGLT2 inhibitors, with higher absolute rates in patients over 65 who may have impaired immune function 12. Urinary tract infections are also modestly more frequent. Starting empagliflozin at 10 mg (rather than 25 mg) and reviewing concurrent diuretics before initiation reduces this risk.

Dosing Adjustments in the Elderly

Lantus doses in elderly patients should be started conservatively, typically 10 units at bedtime, and titrated by 1 to 2 units every 3 days targeting fasting glucose 90 to 130 mg/dL per ADA 2024 guidelines 4. Empagliflozin requires no age-based dose adjustment per the FDA label, but eGFR must be confirmed above 20 before prescribing.

Obesity and Body Weight

Empagliflozin's Weight Advantage

Empagliflozin produces a mean weight loss of 2.0 to 3.2 kg over 24 to 52 weeks through glycosuria (loss of approximately 250 kcal/day as urinary glucose) and fluid loss 13. This is modest compared with GLP-1 agonists but directionally opposite to insulin. For patients already above BMI 35, avoiding insulin-driven weight gain has real clinical value in reducing insulin resistance.

Insulin Glargine and Weight Gain

Insulin glargine produces weight gain averaging 1.5 to 3.0 kg in the first year of therapy. ORIGIN patients on glargine gained 1.61 kg versus a 0.44 kg loss in the standard-care arm at 6.2 years 1. Weight gain worsens insulin resistance, often requiring dose escalation, a cycle that can be difficult to interrupt. Pairing glargine with a GLP-1 receptor agonist or SGLT2 inhibitor mitigates this effect. The fixed-ratio combination product iGlarLixi (Soliqua) pairs glargine with lixisenatide and has shown weight-neutral outcomes 14.

Pregnancy and Women of Reproductive Age

Empagliflozin in Pregnancy

Empagliflozin is classified FDA Pregnancy Category D equivalent (based on animal data showing renal dysmaturation) and is contraindicated during the second and third trimesters per current labeling 15. Women planning pregnancy should switch to insulin before conception. ACOG recommends insulin as the preferred agent for glycemic management in pregnancy 16.

Insulin Glargine in Pregnancy

Insulin glargine has a more extensive safety record in pregnancy. A 2012 meta-analysis in Diabetes Care (N=702 pregnancies) found no statistically significant differences in neonatal outcomes between NPH insulin and glargine during pregnancy 17. Many maternal-fetal medicine specialists prefer NPH for its longer safety track record, but glargine is widely used when NPH causes problematic nocturnal hypoglycemia. Insulin remains the standard of care throughout gestation.

Switching Between Jardiance and Lantus: Clinical Protocol

Clinicians encounter two common switching scenarios: adding or substituting empagliflozin when a patient on glargine is not meeting targets, and conversely, transitioning a patient off empagliflozin to glargine when renal function has declined below eGFR 20 or when glycemia has deteriorated significantly.

Switching From Lantus to Jardiance (or Adding Empagliflozin)

This is less a switch and more an add-on in most cases. ADA 2024 guidance supports adding an SGLT2 inhibitor to basal insulin in patients with established cardiovascular disease or heart failure regardless of HbA1c level 4. When empagliflozin is added to glargine:

• Reduce the glargine dose by 10 to 20% to prevent hypoglycemia from the combined glucose-lowering effect.
• Recheck fasting glucose after 1 to 2 weeks and re-titrate glargine upward if fasting glucose rises above 130 mg/dL.
• Monitor for volume depletion symptoms in the first 2 to 4 weeks, especially if the patient is also on a loop diuretic.

A complete substitution of glargine with empagliflozin is appropriate only if HbA1c is near goal and residual beta-cell function is sufficient. Patients with HbA1c above 10% or type 1 diabetes should not have basal insulin removed entirely.

Switching From Jardiance to Lantus

The two most common clinical triggers are eGFR dropping below 20 mL/min/1.73m² (at which point empagliflozin loses both glycemic and guideline support) and uncontrolled hyperglycemia requiring more potent glucose lowering. When transitioning:

• Start glargine at 0.1 to 0.2 units/kg/day at bedtime and titrate by 2 units every 3 days targeting fasting glucose 80 to 130 mg/dL.
• Discontinue empagliflozin on the same day glargine is initiated.
• Recheck HbA1c at 3 months to confirm adequacy of the new regimen.
• If the switch is driven by heart failure progression or volume concerns, empagliflozin should be discontinued before glargine is started to avoid transient polyuria from the combined diuretic effects.

Comparative Safety Profile

Diabetic Ketoacidosis Risk

Empagliflozin carries a black-box warning for euglycemic diabetic ketoacidosis (DKA), particularly in patients who are fasting, undergoing surgery, or have reduced carbohydrate intake. The incidence is approximately 0.1 to 0.2% per year in type 2 diabetes but rises substantially in type 1 (off-label use) and peri-operative settings 18. Insulin glargine does not cause DKA; it prevents it. Patients undergoing elective procedures should hold empagliflozin for at least 3 to 4 days before surgery per current FDA guidance.

Genital and Urinary Tract Infections

Genital mycotic infections occur in 6 to 10% of women and 3 to 5% of men on empagliflozin 12. Most respond to a single course of oral fluconazole or topical antifungals. Insulin glargine carries no intrinsic infection risk beyond the standard injection-site considerations. Patients with recurrent candidiasis or uncircumcised men may prefer glargine on safety grounds.

Lower Limb Amputation

The CANVAS trial (canagliflozin, not empagliflozin) raised concerns about amputation risk, but EMPA-REG OUTCOME showed no significant increase in amputations with empagliflozin 2. Patients with active foot ulcers or critical limb ischemia warrant careful monitoring if placed on any SGLT2 inhibitor. Insulin glargine has no known amputation signal.

Cost, Access, and Adherence

Empagliflozin's list price in the United States runs approximately $550, $600 per month for brand-name Jardiance; manufacturer copay cards reduce this to $0, $35/month for commercially insured patients. No generic empagliflozin was available in the US as of early 2025. Generic insulin glargine (basaglar, rezvoglar) is available at roughly $80, $150 per month, and Walmart sells ReliOn brand insulin glargine for $88 per vial without insurance 19. Adherence data from real-world claims databases suggest that once-daily oral empagliflozin achieves 12-month persistence rates of 55 to 65%, compared with 40 to 55% for basal insulin due to injection burden and titration complexity 20.

Clinical Decision Summary

Selecting between empagliflozin and insulin glargine is less about which drug is "better" and more about matching the drug's benefit profile to the patient's dominant clinical problem.

For patients with established cardiovascular disease or heart failure: empagliflozin first, unless HbA1c is above 10% or type 1 diabetes is present.

For patients with CKD stages 3a, 4 (eGFR 20 to 59): empagliflozin for renal protection alongside glycemic management, with glargine added if HbA1c remains above 8.0%.

For patients who are pregnant or planning pregnancy: insulin glargine, full stop. Empagliflozin must be discontinued before conception or as soon as pregnancy is confirmed.

For elderly patients with high hypoglycemia risk: empagliflozin is preferred if eGFR is adequate, but start at 10 mg and review diuretics first.

For patients requiring significant HbA1c reduction from a high baseline (>9.5%): insulin glargine provides more reliable and titratable glycemic lowering. Empagliflozin may be added once the patient is closer to goal.

The ADA 2024 Standards of Care summarize the hierarchy this way: "Compelling comorbidities, including cardiovascular disease, heart failure, and chronic kidney disease, should drive agent selection independently of glucose-lowering efficacy." 4

A single number worth keeping in mind: in EMPA-REG OUTCOME, the number needed to treat to prevent one cardiovascular death over 3 years was 39 patients 2. For a busy clinic seeing 200 patients per year with type 2 diabetes and established cardiovascular disease, systematically identifying and prescribing empagliflozin to eligible patients could prevent 5 cardiovascular deaths annually.